{"gene":"VMA21","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":2009,"finding":"VMA21 is an essential assembly chaperone of the vacuolar ATPase (V-ATPase), the principal mammalian proton pump complex; decreased VMA21 raises lysosomal pH, reduces lysosomal degradative ability, blocks autophagy, reduces cellular free amino acids, upregulates mTOR-dependent macroautophagy, and results in proliferation of large ineffective autolysosomes that vacuolate the cell, causing X-linked myopathy with excessive autophagy (XMEA).","method":"Genetic mapping of XMEA mutations to hypomorphic VMA21 alleles, V-ATPase assembly assays, lysosomal pH measurement, autophagy flux assays, mTOR pathway analysis, yeast ortholog functional comparison","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (genetics, biochemistry, cell biology) in a single landmark paper, replicated in a follow-up Acta Neuropathologica paper","pmids":["19379691"],"is_preprint":false},{"year":2013,"finding":"VMA21 is the diverged human ortholog of yeast Vma21p and functions as an essential V-ATPase assembly chaperone; hypomorphic XMEA mutations reduce VMA21 expression, raising lysosomal pH, impairing lysosomal degradation, blocking autophagy, reducing free amino acids, downregulating mTORC1, and causing macroautophagic overcompensation leading to cell vacuolation and atrophy.","method":"Patient mutation analysis, V-ATPase assembly assays, lysosomal pH measurements, mTORC1 pathway assays, autophagy flux assays, muscle biopsy histology","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 1-2 — replication of foundational Cell 2009 paper with additional mechanistic detail, multiple orthogonal methods","pmids":["23315026"],"is_preprint":false},{"year":2014,"finding":"Non-coding (intronic and 3'UTR) microdeletions in VMA21 reduce VMA21 expression and cause a more severe XMEA phenotype, confirming that VMA21 protein levels are directly proportional to disease severity and lysosomal pH dysregulation.","method":"Genetic sequencing of non-coding VMA21 deletions, patient clinical characterization, mutation-expression correlation","journal":"Neuromuscular disorders : NMD","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic evidence linking VMA21 expression level to phenotype severity, single lab","pmids":["25683699"],"is_preprint":false},{"year":2020,"finding":"VMA21 pathogenic variants cause V-ATPase misassembly and dysfunction, impairing lysosomal acidification, leading to lipid droplet accumulation in autolysosomes, ER stress, sequestration of unesterified cholesterol in lysosomes, and activation of SREBP-mediated cholesterol synthesis, resulting in a congenital disorder of glycosylation with autophagic liver disease.","method":"Patient variant identification, V-ATPase assembly assays, lysosomal acidification assays, lipid droplet imaging, cholesterol trafficking assays, ER stress markers, SREBP pathway analysis","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and cell biological methods establishing mechanistic consequences of VMA21 variants in liver","pmids":["32145091"],"is_preprint":false},{"year":2022,"finding":"Follicular lymphoma-associated VMA21 hotspot mutation p.93X removes a C-terminal non-canonical ER retrieval signal, causing VMA21 mislocalization from ER to lysosomes, impairing V-ATPase activity, preventing full lysosomal acidification, depleting cytoplasmic amino acids, and activating compensatory autophagy that creates a survival dependency targetable by ULK1 inhibitors.","method":"Mutation analysis, subcellular localization (fluorescence microscopy), lysosomal metabolomics (Lyso-IP), V-ATPase activity assays, autophagy flux assays (multiple complementary assays), high-throughput drug screening, yeast functional assays","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 — multiple complementary methods in human and yeast cells, mechanistic pathway established with pharmacological validation","pmids":["35287545"],"is_preprint":false},{"year":2022,"finding":"The FL-associated VMA21 Vma21[Δ66-77] mutation (corresponding to p.93X) impairs V-ATPase assembly as shown by decreased vacuolar levels of V0 subunits and a Vph1 stability assay, and significantly reduces vacuolar levels of histidine, lysine, and arginine.","method":"Yeast genetic model, V0 subunit localization, Vph1 stability assay, vacuolar amino acid metabolomics","journal":"Autophagy reports","confidence":"Medium","confidence_rationale":"Tier 1-2 — direct biochemical assays in yeast model but single lab","pmids":["37389034"],"is_preprint":false},{"year":2023,"finding":"VMA21 encodes two protein isoforms: a ubiquitous short isoform (VMA21-101) and a muscle-specific long isoform (VMA21-120); VMA21-120 is predominantly expressed in skeletal muscle, rapidly upregulated upon muscle differentiation, accumulated during development/regeneration/denervation, and both isoforms localize to the sarcoplasmic reticulum of muscle cells and interact with the V-ATPase; XMEA mutations cause loss of both isoforms.","method":"RT-PCR and Western blot isoform identification, immunofluorescence localization, co-immunoprecipitation with V-ATPase, muscle differentiation assays, mouse and human muscle precursor cell models, in vivo mouse muscle analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal co-IP, direct localization, multiple model systems (mouse and human), multiple orthogonal methods in single study","pmids":["37756622"],"is_preprint":false},{"year":2023,"finding":"Aerobic exercise reverses V-ATPase dysfunction and autophagy-lysosomal deficits in Alzheimer's disease mice by upregulating VMA21 levels via ADRB2/β2-adrenergic receptor and AMPK-mTOR signaling, enhancing Aβ clearance through the autophagy-lysosomal pathway.","method":"Mouse AD model (APP-PSEN1), pharmacological ADRB2 inhibition with propranolol, VMA21 protein level measurement, V-ATPase activity assay, autophagy flux assays, Aβ pathology quantification, cognitive testing","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — defined pathway placement (ADRB2→VMA21→V-ATPase→autophagy) with pharmacological validation, but single lab","pmids":["37964627"],"is_preprint":false},{"year":2024,"finding":"VMA21 stabilizes TCIRG1 protein expression by binding to TCIRG1 and inhibiting its ubiquitination-mediated degradation, thereby promoting proliferation, invasion, and immune escape in triple-negative breast cancer cells.","method":"Co-immunoprecipitation, ubiquitination assay, VMA21 knockdown in TNBC cell lines, CD8+ T cell co-culture assay, xenograft mouse model","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal co-IP plus ubiquitination assay establishing VMA21-TCIRG1 interaction mechanism, single lab","pmids":["39267677"],"is_preprint":false},{"year":2000,"finding":"X-linked myopathy with excessive autophagy (XMEA) was genetically mapped to the Xq28 region, establishing the chromosomal locus of the VMA21 gene and ruling out allelic identity with Emery-Dreifuss muscular dystrophy.","method":"Linkage analysis with 32 polymorphic X-chromosome markers, multipoint LOD score analysis, Sanger sequencing of emerin gene","journal":"European journal of human genetics : EJHG","confidence":"Medium","confidence_rationale":"Tier 2 — genetic linkage establishing disease locus, prerequisite for later gene identification","pmids":["10757644"],"is_preprint":false}],"current_model":"VMA21 is an ER-resident assembly chaperone (existing as ubiquitous VMA21-101 and muscle-specific VMA21-120 isoforms) that is essential for V-ATPase proton pump complex assembly; its deficiency impairs lysosomal acidification and autophagic degradation, depletes cytoplasmic amino acids, dysregulates mTORC1/mTOR signaling, causes macroautophagic overcompensation, and leads to tissue-specific pathology (skeletal muscle vacuolation in XMEA, hepatic steatosis/ER stress in CDG); certain FL-associated mutations remove a C-terminal ER retrieval signal causing VMA21 mislocalization to lysosomes and compensatory autophagy, while VMA21 also stabilizes TCIRG1 by inhibiting its ubiquitination degradation in cancer contexts."},"narrative":{"teleology":[{"year":2000,"claim":"Mapping the XMEA disease locus to Xq28 established the chromosomal region harboring VMA21, enabling its subsequent identification as the causative gene.","evidence":"Linkage analysis with 32 X-chromosome markers in XMEA families","pmids":["10757644"],"confidence":"Medium","gaps":["Gene itself not yet identified","No functional characterization of the locus product"]},{"year":2009,"claim":"Identification of hypomorphic VMA21 mutations as the cause of XMEA established VMA21 as the mammalian V-ATPase assembly chaperone and revealed the mechanistic cascade from impaired proton pump assembly through lysosomal alkalinization, autophagy blockade, amino acid depletion, mTOR dysregulation, and compensatory macroautophagy to cell vacuolation.","evidence":"Genetic mapping, V-ATPase assembly assays, lysosomal pH measurement, autophagy flux, mTOR pathway analysis, yeast ortholog complementation","pmids":["19379691"],"confidence":"High","gaps":["Tissue-specific mechanisms of skeletal muscle selectivity unknown","Structural basis of VMA21-V0 interaction not determined","No isoform-level characterization"]},{"year":2013,"claim":"Replication and extension of the XMEA mechanism confirmed VMA21 as the diverged human ortholog of yeast Vma21p and solidified the pathway from V-ATPase misassembly through mTORC1 downregulation to autophagic overcompensation and atrophy.","evidence":"Patient mutation analysis, V-ATPase assembly and lysosomal pH assays, mTORC1 and autophagy flux measurements, muscle biopsy histology","pmids":["23315026"],"confidence":"High","gaps":["No explanation for why only skeletal muscle is affected despite ubiquitous V-ATPase expression","No non-coding mutation analysis"]},{"year":2014,"claim":"Discovery that non-coding VMA21 microdeletions cause severe XMEA demonstrated that VMA21 protein level is directly proportional to disease severity and lysosomal function.","evidence":"Genetic sequencing of intronic and 3ʹUTR deletions with clinical correlation","pmids":["25683699"],"confidence":"Medium","gaps":["Precise regulatory elements disrupted not mapped","No quantitative dose–response curve for VMA21 levels versus lysosomal pH established"]},{"year":2020,"claim":"Identification of VMA21 variants causing congenital disorder of glycosylation with liver disease revealed that V-ATPase dysfunction extends beyond muscle to produce hepatic steatosis, ER stress, lysosomal cholesterol sequestration, and SREBP-mediated lipogenesis.","evidence":"Patient variant analysis, V-ATPase assembly assays, lipid droplet imaging, cholesterol trafficking, ER stress marker quantification, SREBP pathway analysis","pmids":["32145091"],"confidence":"High","gaps":["Genotype–phenotype rules distinguishing muscle versus liver presentations unclear","Whether glycosylation defect is primary or secondary to lysosomal pH change not resolved"]},{"year":2022,"claim":"Characterization of the follicular lymphoma hotspot mutation p.93X revealed a C-terminal non-canonical ER retrieval signal whose loss mislocalizes VMA21 to lysosomes, impairing V-ATPase activity and creating an autophagy-dependent survival vulnerability targetable by ULK1 inhibition.","evidence":"Subcellular localization imaging, lysosomal metabolomics (Lyso-IP), V-ATPase activity assays, autophagy flux assays, high-throughput drug screen, yeast functional assays","pmids":["35287545","37389034"],"confidence":"High","gaps":["In vivo FL therapeutic efficacy of ULK1 inhibition not tested","Whether mislocalized VMA21 has dominant-negative or loss-of-function behavior in lymphocytes not distinguished"]},{"year":2023,"claim":"Discovery of two VMA21 isoforms — ubiquitous VMA21-101 and muscle-specific VMA21-120 — explained the tissue-selective vulnerability in XMEA: VMA21-120 is upregulated during myogenic differentiation and muscle regeneration, and XMEA mutations eliminate both isoforms.","evidence":"RT-PCR, Western blot, immunofluorescence, co-immunoprecipitation with V-ATPase, muscle differentiation and in vivo mouse models","pmids":["37756622"],"confidence":"High","gaps":["Distinct functional contributions of VMA21-101 versus VMA21-120 to V-ATPase assembly not dissected","No structural data on either isoform"]},{"year":2023,"claim":"Demonstration that aerobic exercise upregulates VMA21 via ADRB2–AMPK–mTOR signaling in an Alzheimer's disease mouse model linked VMA21-dependent V-ATPase function to amyloid-β clearance through the autophagy–lysosome pathway.","evidence":"APP-PSEN1 mouse model, propranolol-mediated ADRB2 blockade, VMA21/V-ATPase activity measurement, autophagy and Aβ quantification","pmids":["37964627"],"confidence":"Medium","gaps":["Mechanism by which ADRB2 signaling transcriptionally or post-transcriptionally regulates VMA21 not defined","Not replicated in independent AD cohorts or models"]},{"year":2024,"claim":"VMA21 was shown to stabilize the V-ATPase a3 subunit TCIRG1 by direct binding and inhibition of its ubiquitination-mediated degradation, linking VMA21 to tumor proliferation and immune evasion in triple-negative breast cancer.","evidence":"Co-immunoprecipitation, ubiquitination assay, VMA21 knockdown in TNBC cell lines, CD8⁺ T cell co-culture, xenograft model","pmids":["39267677"],"confidence":"Medium","gaps":["Whether VMA21-TCIRG1 stabilization is independent of canonical V-ATPase assembly chaperone function not clarified","No identification of the E3 ligase antagonized by VMA21","Single-lab finding awaiting independent replication"]},{"year":null,"claim":"The structural basis of VMA21's interaction with V0 subunits, the distinct functional roles of VMA21-101 versus VMA21-120 in V-ATPase assembly, and the genotype–phenotype rules governing muscle versus liver disease remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of mammalian VMA21 or VMA21–V0 complex","Isoform-specific V-ATPase assembly contributions not dissected","Determinants of tissue-selective pathology (muscle vs liver vs lymphoma) undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[0,1,4,6]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[0,1,4,7]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,3]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,7]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,1,6]}],"complexes":["V-ATPase (V0 sector assembly intermediate)"],"partners":["TCIRG1","ATP6V0A1","ATP6V0D1"],"other_free_text":[]},"mechanistic_narrative":"VMA21 is an endoplasmic reticulum-resident assembly chaperone essential for biogenesis of the vacuolar H⁺-ATPase (V-ATPase), the principal mammalian proton pump, and its deficiency impairs lysosomal acidification, autophagic degradation, and cellular amino acid homeostasis. VMA21 exists as a ubiquitous short isoform (VMA21-101) and a muscle-specific long isoform (VMA21-120) that is upregulated during myogenic differentiation; both isoforms localize to the sarcoplasmic reticulum and interact with V-ATPase subunits, and XMEA-causing mutations ablate both isoforms [PMID:37756622]. Hypomorphic VMA21 mutations cause X-linked myopathy with excessive autophagy (XMEA) through reduced V-ATPase assembly, elevated lysosomal pH, mTORC1 downregulation, and compensatory macroautophagy leading to cell vacuolation, while distinct pathogenic variants produce a congenital disorder of glycosylation with autophagic liver disease featuring lipid droplet accumulation, ER stress, and SREBP-mediated cholesterol dysregulation [PMID:19379691, PMID:32145091]. A follicular lymphoma-associated truncation removes a C-terminal ER retrieval signal, mislocalizing VMA21 to lysosomes and creating an autophagy-dependent survival vulnerability targetable by ULK1 inhibitors, and VMA21 additionally stabilizes the V-ATPase subunit TCIRG1 by inhibiting its ubiquitination-mediated degradation [PMID:35287545, PMID:39267677]."},"prefetch_data":{"uniprot":{"accession":"Q3ZAQ7","full_name":"Vacuolar ATPase assembly integral membrane protein VMA21","aliases":["Myopathy with excessive autophagy protein"],"length_aa":101,"mass_kda":11.4,"function":"Required for the assembly of the V0 complex of the vacuolar ATPase (V-ATPase) in the endoplasmic reticulum","subcellular_location":"Endoplasmic reticulum membrane; Endoplasmic reticulum-Golgi intermediate compartment membrane; Cytoplasmic vesicle, COPII-coated vesicle membrane","url":"https://www.uniprot.org/uniprotkb/Q3ZAQ7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VMA21","classification":"Not Classified","n_dependent_lines":381,"n_total_lines":1208,"dependency_fraction":0.31539735099337746},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ATP6V0A2","stoichiometry":10.0},{"gene":"CANX","stoichiometry":4.0},{"gene":"ATP6V1F","stoichiometry":0.2},{"gene":"TMED10","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/VMA21","total_profiled":1310},"omim":[{"mim_id":"310440","title":"MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX","url":"https://www.omim.org/entry/310440"},{"mim_id":"300913","title":"VACUOLAR ATPase ASSEMBLY FACTOR VMA21; VMA21","url":"https://www.omim.org/entry/300913"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/VMA21"},"hgnc":{"alias_symbol":["XMEA"],"prev_symbol":["MEAX"]},"alphafold":{"accession":"Q3ZAQ7","domains":[{"cath_id":"1.10.287","chopping":"23-97","consensus_level":"high","plddt":72.6215,"start":23,"end":97}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q3ZAQ7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q3ZAQ7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q3ZAQ7-F1-predicted_aligned_error_v6.png","plddt_mean":70.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VMA21","jax_strain_url":"https://www.jax.org/strain/search?query=VMA21"},"sequence":{"accession":"Q3ZAQ7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q3ZAQ7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q3ZAQ7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q3ZAQ7"}},"corpus_meta":[{"pmid":"29343508","id":"PMC_29343508","title":"Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein.","date":"2018","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29343508","citation_count":243,"is_preprint":false},{"pmid":"23315026","id":"PMC_23315026","title":"VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy.","date":"2013","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/23315026","citation_count":111,"is_preprint":false},{"pmid":"32827242","id":"PMC_32827242","title":"Circular RNA VMA21 ameliorates sepsis-associated acute kidney injury by regulating miR-9-3p/SMG1/inflammation axis and oxidative stress.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32827242","citation_count":66,"is_preprint":false},{"pmid":"31297866","id":"PMC_31297866","title":"lncRNA ZFPM2-AS1 promotes proliferation via miR-18b-5p/VMA21 axis in lung adenocarcinoma.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31297866","citation_count":51,"is_preprint":false},{"pmid":"19379691","id":"PMC_19379691","title":"VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19379691","citation_count":51,"is_preprint":false},{"pmid":"32145091","id":"PMC_32145091","title":"Mutations in the V-ATPase Assembly Factor VMA21 Cause a Congenital Disorder of Glycosylation With Autophagic Liver Disease.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32145091","citation_count":43,"is_preprint":false},{"pmid":"32058209","id":"PMC_32058209","title":"Non-coding RNA LOXL1-AS1 exhibits oncogenic activity in ovarian cancer via regulation of miR-18b-5p/VMA21 axis.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32058209","citation_count":36,"is_preprint":false},{"pmid":"25683699","id":"PMC_25683699","title":"Non-coding VMA21 deletions cause X-linked myopathy with excessive autophagy.","date":"2014","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/25683699","citation_count":30,"is_preprint":false},{"pmid":"37964627","id":"PMC_37964627","title":"Aerobic exercise attenuates autophagy-lysosomal flux deficits by ADRB2/β2-adrenergic receptor-mediated V-ATPase assembly factor VMA21 signaling in APP-PSEN1/PS1 mice.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37964627","citation_count":24,"is_preprint":false},{"pmid":"31793712","id":"PMC_31793712","title":"Protective impacts of circular RNA VMA21 on lipopolysaccharide-engendered WI-38 cells injury via mediating microRNA-142-3p.","date":"2019","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31793712","citation_count":24,"is_preprint":false},{"pmid":"10757644","id":"PMC_10757644","title":"Linkage of X-linked myopathy with excessive autophagy (XMEA) to Xq28.","date":"2000","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/10757644","citation_count":22,"is_preprint":false},{"pmid":"34507559","id":"PMC_34507559","title":"Hsa_circ_0001361 facilitates the progress of lung adenocarcinoma cells via targeting miR-525-5p/VMA21 axis.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34507559","citation_count":18,"is_preprint":false},{"pmid":"33247967","id":"PMC_33247967","title":"Long non-coding RNA LINC00665 promotes melanoma cell growth and migration via regulating the miR-224-5p/VMA21 axis.","date":"2020","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33247967","citation_count":16,"is_preprint":false},{"pmid":"35172672","id":"PMC_35172672","title":"Circular RNA VMA21 ameliorates lung injury in septic rat via targeting microRNA-497-5p/CD2-associated protein axis.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35172672","citation_count":15,"is_preprint":false},{"pmid":"35287545","id":"PMC_35287545","title":"Follicular lymphoma-associated mutations in the V-ATPase chaperone VMA21 activate autophagy creating a targetable dependency.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35287545","citation_count":15,"is_preprint":false},{"pmid":"34275889","id":"PMC_34275889","title":"LncRNA LINC00858 enhances cervical cancer cell growth through miR-3064-5p/ VMA21 axis.","date":"2021","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/34275889","citation_count":13,"is_preprint":false},{"pmid":"35378300","id":"PMC_35378300","title":"Circular RNA VMA21 ameliorates IL-1β-engendered chondrocyte injury through the miR-495-3p/FBWX7 signaling axis.","date":"2022","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/35378300","citation_count":10,"is_preprint":false},{"pmid":"34350833","id":"PMC_34350833","title":"circ_VMA21 protects WI-38 cells against LPS-induced apoptotic and inflammatory injury by acting on the miR-409-3p/KLF4 axis.","date":"2021","source":"General physiology and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/34350833","citation_count":10,"is_preprint":false},{"pmid":"36553512","id":"PMC_36553512","title":"Novel Intronic Mutation in VMA21 Causing Severe Phenotype of X-Linked Myopathy with Excessive Autophagy-Case Report.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36553512","citation_count":8,"is_preprint":false},{"pmid":"37756622","id":"PMC_37756622","title":"Identification of a muscle-specific isoform of VMA21 as a potent actor in X-linked myopathy with excessive autophagy pathogenesis.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37756622","citation_count":5,"is_preprint":false},{"pmid":"19379689","id":"PMC_19379689","title":"VMA21 deficiency: a case of myocyte indigestion.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19379689","citation_count":5,"is_preprint":false},{"pmid":"28265396","id":"PMC_28265396","title":"Prenatal diagnosis of X-linked myopathy associated with a VMA21 gene mutation afforded through a novel targeted exome sequencing strategy applied in fetuses with abnormal ultrasound findings.","date":"2017","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/28265396","citation_count":4,"is_preprint":false},{"pmid":"35138580","id":"PMC_35138580","title":"Circular RNA Derived from Vacuolar ATPase Assembly Factor VMA21 Suppresses Lipopolysaccharide-Induced Apoptosis of Chondrocytes in Osteoarthritis (OA) by Decreasing Mature miR-103 Production.","date":"2022","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35138580","citation_count":3,"is_preprint":false},{"pmid":"38736558","id":"PMC_38736558","title":"Identification of a Novel Intronic Mutation in VMA21 Associated with a Classical Form of X-Linked Myopathy with Autophagy.","date":"2024","source":"Global medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38736558","citation_count":2,"is_preprint":false},{"pmid":"37389034","id":"PMC_37389034","title":"Follicular lymphoma-associated mutations in the V-ATPase chaperone Vma21 activate autophagy by dysfunctional V-ATPase assembly.","date":"2022","source":"Autophagy reports","url":"https://pubmed.ncbi.nlm.nih.gov/37389034","citation_count":1,"is_preprint":false},{"pmid":"40033998","id":"PMC_40033998","title":"Recent advances in the clinical spectrum and pathomechanisms associated with X-linked myopathy with excessive autophagy and other VMA21-related disorders.","date":"2025","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40033998","citation_count":0,"is_preprint":false},{"pmid":"41307411","id":"PMC_41307411","title":"Clinical, morphological, and molecular characterization of patients with X-linked myopathy with excessive autophagy (XMEA).","date":"2026","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41307411","citation_count":0,"is_preprint":false},{"pmid":"39267677","id":"PMC_39267677","title":"VMA21: unveiling a novel oncogene that facilitates immune evasion in triple-negative breast cancer through TCIRG1 protein stability regulation.","date":"2024","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39267677","citation_count":0,"is_preprint":false},{"pmid":"39973400","id":"PMC_39973400","title":"A novel variant in VMA21 causing adult-onset phenotype of X-linked myopathy with excessive autophagy with cardiac involvement in a Chinese patient.","date":"2024","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39973400","citation_count":0,"is_preprint":false},{"pmid":"38676026","id":"PMC_38676026","title":"XMEA: A New Hybrid Diamond Multielectrode Array for the In Situ Assessment of the Radiation Dose Enhancement by Nanoparticles.","date":"2024","source":"Sensors (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38676026","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.18.654701","title":"Engineering precision zebrafish alleles of human disease","date":"2025-05-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.18.654701","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15787,"output_tokens":2690,"usd":0.043855},"stage2":{"model":"claude-opus-4-6","input_tokens":6013,"output_tokens":2703,"usd":0.14646},"total_usd":0.190315,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"VMA21 is an essential assembly chaperone of the vacuolar ATPase (V-ATPase), the principal mammalian proton pump complex; decreased VMA21 raises lysosomal pH, reduces lysosomal degradative ability, blocks autophagy, reduces cellular free amino acids, upregulates mTOR-dependent macroautophagy, and results in proliferation of large ineffective autolysosomes that vacuolate the cell, causing X-linked myopathy with excessive autophagy (XMEA).\",\n      \"method\": \"Genetic mapping of XMEA mutations to hypomorphic VMA21 alleles, V-ATPase assembly assays, lysosomal pH measurement, autophagy flux assays, mTOR pathway analysis, yeast ortholog functional comparison\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (genetics, biochemistry, cell biology) in a single landmark paper, replicated in a follow-up Acta Neuropathologica paper\",\n      \"pmids\": [\"19379691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"VMA21 is the diverged human ortholog of yeast Vma21p and functions as an essential V-ATPase assembly chaperone; hypomorphic XMEA mutations reduce VMA21 expression, raising lysosomal pH, impairing lysosomal degradation, blocking autophagy, reducing free amino acids, downregulating mTORC1, and causing macroautophagic overcompensation leading to cell vacuolation and atrophy.\",\n      \"method\": \"Patient mutation analysis, V-ATPase assembly assays, lysosomal pH measurements, mTORC1 pathway assays, autophagy flux assays, muscle biopsy histology\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — replication of foundational Cell 2009 paper with additional mechanistic detail, multiple orthogonal methods\",\n      \"pmids\": [\"23315026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Non-coding (intronic and 3'UTR) microdeletions in VMA21 reduce VMA21 expression and cause a more severe XMEA phenotype, confirming that VMA21 protein levels are directly proportional to disease severity and lysosomal pH dysregulation.\",\n      \"method\": \"Genetic sequencing of non-coding VMA21 deletions, patient clinical characterization, mutation-expression correlation\",\n      \"journal\": \"Neuromuscular disorders : NMD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic evidence linking VMA21 expression level to phenotype severity, single lab\",\n      \"pmids\": [\"25683699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VMA21 pathogenic variants cause V-ATPase misassembly and dysfunction, impairing lysosomal acidification, leading to lipid droplet accumulation in autolysosomes, ER stress, sequestration of unesterified cholesterol in lysosomes, and activation of SREBP-mediated cholesterol synthesis, resulting in a congenital disorder of glycosylation with autophagic liver disease.\",\n      \"method\": \"Patient variant identification, V-ATPase assembly assays, lysosomal acidification assays, lipid droplet imaging, cholesterol trafficking assays, ER stress markers, SREBP pathway analysis\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and cell biological methods establishing mechanistic consequences of VMA21 variants in liver\",\n      \"pmids\": [\"32145091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Follicular lymphoma-associated VMA21 hotspot mutation p.93X removes a C-terminal non-canonical ER retrieval signal, causing VMA21 mislocalization from ER to lysosomes, impairing V-ATPase activity, preventing full lysosomal acidification, depleting cytoplasmic amino acids, and activating compensatory autophagy that creates a survival dependency targetable by ULK1 inhibitors.\",\n      \"method\": \"Mutation analysis, subcellular localization (fluorescence microscopy), lysosomal metabolomics (Lyso-IP), V-ATPase activity assays, autophagy flux assays (multiple complementary assays), high-throughput drug screening, yeast functional assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple complementary methods in human and yeast cells, mechanistic pathway established with pharmacological validation\",\n      \"pmids\": [\"35287545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The FL-associated VMA21 Vma21[Δ66-77] mutation (corresponding to p.93X) impairs V-ATPase assembly as shown by decreased vacuolar levels of V0 subunits and a Vph1 stability assay, and significantly reduces vacuolar levels of histidine, lysine, and arginine.\",\n      \"method\": \"Yeast genetic model, V0 subunit localization, Vph1 stability assay, vacuolar amino acid metabolomics\",\n      \"journal\": \"Autophagy reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical assays in yeast model but single lab\",\n      \"pmids\": [\"37389034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VMA21 encodes two protein isoforms: a ubiquitous short isoform (VMA21-101) and a muscle-specific long isoform (VMA21-120); VMA21-120 is predominantly expressed in skeletal muscle, rapidly upregulated upon muscle differentiation, accumulated during development/regeneration/denervation, and both isoforms localize to the sarcoplasmic reticulum of muscle cells and interact with the V-ATPase; XMEA mutations cause loss of both isoforms.\",\n      \"method\": \"RT-PCR and Western blot isoform identification, immunofluorescence localization, co-immunoprecipitation with V-ATPase, muscle differentiation assays, mouse and human muscle precursor cell models, in vivo mouse muscle analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal co-IP, direct localization, multiple model systems (mouse and human), multiple orthogonal methods in single study\",\n      \"pmids\": [\"37756622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Aerobic exercise reverses V-ATPase dysfunction and autophagy-lysosomal deficits in Alzheimer's disease mice by upregulating VMA21 levels via ADRB2/β2-adrenergic receptor and AMPK-mTOR signaling, enhancing Aβ clearance through the autophagy-lysosomal pathway.\",\n      \"method\": \"Mouse AD model (APP-PSEN1), pharmacological ADRB2 inhibition with propranolol, VMA21 protein level measurement, V-ATPase activity assay, autophagy flux assays, Aβ pathology quantification, cognitive testing\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined pathway placement (ADRB2→VMA21→V-ATPase→autophagy) with pharmacological validation, but single lab\",\n      \"pmids\": [\"37964627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VMA21 stabilizes TCIRG1 protein expression by binding to TCIRG1 and inhibiting its ubiquitination-mediated degradation, thereby promoting proliferation, invasion, and immune escape in triple-negative breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, VMA21 knockdown in TNBC cell lines, CD8+ T cell co-culture assay, xenograft mouse model\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal co-IP plus ubiquitination assay establishing VMA21-TCIRG1 interaction mechanism, single lab\",\n      \"pmids\": [\"39267677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"X-linked myopathy with excessive autophagy (XMEA) was genetically mapped to the Xq28 region, establishing the chromosomal locus of the VMA21 gene and ruling out allelic identity with Emery-Dreifuss muscular dystrophy.\",\n      \"method\": \"Linkage analysis with 32 polymorphic X-chromosome markers, multipoint LOD score analysis, Sanger sequencing of emerin gene\",\n      \"journal\": \"European journal of human genetics : EJHG\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic linkage establishing disease locus, prerequisite for later gene identification\",\n      \"pmids\": [\"10757644\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VMA21 is an ER-resident assembly chaperone (existing as ubiquitous VMA21-101 and muscle-specific VMA21-120 isoforms) that is essential for V-ATPase proton pump complex assembly; its deficiency impairs lysosomal acidification and autophagic degradation, depletes cytoplasmic amino acids, dysregulates mTORC1/mTOR signaling, causes macroautophagic overcompensation, and leads to tissue-specific pathology (skeletal muscle vacuolation in XMEA, hepatic steatosis/ER stress in CDG); certain FL-associated mutations remove a C-terminal ER retrieval signal causing VMA21 mislocalization to lysosomes and compensatory autophagy, while VMA21 also stabilizes TCIRG1 by inhibiting its ubiquitination degradation in cancer contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"VMA21 is an endoplasmic reticulum-resident assembly chaperone essential for biogenesis of the vacuolar H⁺-ATPase (V-ATPase), the principal mammalian proton pump, and its deficiency impairs lysosomal acidification, autophagic degradation, and cellular amino acid homeostasis. VMA21 exists as a ubiquitous short isoform (VMA21-101) and a muscle-specific long isoform (VMA21-120) that is upregulated during myogenic differentiation; both isoforms localize to the sarcoplasmic reticulum and interact with V-ATPase subunits, and XMEA-causing mutations ablate both isoforms [PMID:37756622]. Hypomorphic VMA21 mutations cause X-linked myopathy with excessive autophagy (XMEA) through reduced V-ATPase assembly, elevated lysosomal pH, mTORC1 downregulation, and compensatory macroautophagy leading to cell vacuolation, while distinct pathogenic variants produce a congenital disorder of glycosylation with autophagic liver disease featuring lipid droplet accumulation, ER stress, and SREBP-mediated cholesterol dysregulation [PMID:19379691, PMID:32145091]. A follicular lymphoma-associated truncation removes a C-terminal ER retrieval signal, mislocalizing VMA21 to lysosomes and creating an autophagy-dependent survival vulnerability targetable by ULK1 inhibitors, and VMA21 additionally stabilizes the V-ATPase subunit TCIRG1 by inhibiting its ubiquitination-mediated degradation [PMID:35287545, PMID:39267677].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping the XMEA disease locus to Xq28 established the chromosomal region harboring VMA21, enabling its subsequent identification as the causative gene.\",\n      \"evidence\": \"Linkage analysis with 32 X-chromosome markers in XMEA families\",\n      \"pmids\": [\"10757644\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Gene itself not yet identified\", \"No functional characterization of the locus product\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of hypomorphic VMA21 mutations as the cause of XMEA established VMA21 as the mammalian V-ATPase assembly chaperone and revealed the mechanistic cascade from impaired proton pump assembly through lysosomal alkalinization, autophagy blockade, amino acid depletion, mTOR dysregulation, and compensatory macroautophagy to cell vacuolation.\",\n      \"evidence\": \"Genetic mapping, V-ATPase assembly assays, lysosomal pH measurement, autophagy flux, mTOR pathway analysis, yeast ortholog complementation\",\n      \"pmids\": [\"19379691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific mechanisms of skeletal muscle selectivity unknown\", \"Structural basis of VMA21-V0 interaction not determined\", \"No isoform-level characterization\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Replication and extension of the XMEA mechanism confirmed VMA21 as the diverged human ortholog of yeast Vma21p and solidified the pathway from V-ATPase misassembly through mTORC1 downregulation to autophagic overcompensation and atrophy.\",\n      \"evidence\": \"Patient mutation analysis, V-ATPase assembly and lysosomal pH assays, mTORC1 and autophagy flux measurements, muscle biopsy histology\",\n      \"pmids\": [\"23315026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No explanation for why only skeletal muscle is affected despite ubiquitous V-ATPase expression\", \"No non-coding mutation analysis\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that non-coding VMA21 microdeletions cause severe XMEA demonstrated that VMA21 protein level is directly proportional to disease severity and lysosomal function.\",\n      \"evidence\": \"Genetic sequencing of intronic and 3ʹUTR deletions with clinical correlation\",\n      \"pmids\": [\"25683699\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise regulatory elements disrupted not mapped\", \"No quantitative dose–response curve for VMA21 levels versus lysosomal pH established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of VMA21 variants causing congenital disorder of glycosylation with liver disease revealed that V-ATPase dysfunction extends beyond muscle to produce hepatic steatosis, ER stress, lysosomal cholesterol sequestration, and SREBP-mediated lipogenesis.\",\n      \"evidence\": \"Patient variant analysis, V-ATPase assembly assays, lipid droplet imaging, cholesterol trafficking, ER stress marker quantification, SREBP pathway analysis\",\n      \"pmids\": [\"32145091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype rules distinguishing muscle versus liver presentations unclear\", \"Whether glycosylation defect is primary or secondary to lysosomal pH change not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Characterization of the follicular lymphoma hotspot mutation p.93X revealed a C-terminal non-canonical ER retrieval signal whose loss mislocalizes VMA21 to lysosomes, impairing V-ATPase activity and creating an autophagy-dependent survival vulnerability targetable by ULK1 inhibition.\",\n      \"evidence\": \"Subcellular localization imaging, lysosomal metabolomics (Lyso-IP), V-ATPase activity assays, autophagy flux assays, high-throughput drug screen, yeast functional assays\",\n      \"pmids\": [\"35287545\", \"37389034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo FL therapeutic efficacy of ULK1 inhibition not tested\", \"Whether mislocalized VMA21 has dominant-negative or loss-of-function behavior in lymphocytes not distinguished\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery of two VMA21 isoforms — ubiquitous VMA21-101 and muscle-specific VMA21-120 — explained the tissue-selective vulnerability in XMEA: VMA21-120 is upregulated during myogenic differentiation and muscle regeneration, and XMEA mutations eliminate both isoforms.\",\n      \"evidence\": \"RT-PCR, Western blot, immunofluorescence, co-immunoprecipitation with V-ATPase, muscle differentiation and in vivo mouse models\",\n      \"pmids\": [\"37756622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct functional contributions of VMA21-101 versus VMA21-120 to V-ATPase assembly not dissected\", \"No structural data on either isoform\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that aerobic exercise upregulates VMA21 via ADRB2–AMPK–mTOR signaling in an Alzheimer's disease mouse model linked VMA21-dependent V-ATPase function to amyloid-β clearance through the autophagy–lysosome pathway.\",\n      \"evidence\": \"APP-PSEN1 mouse model, propranolol-mediated ADRB2 blockade, VMA21/V-ATPase activity measurement, autophagy and Aβ quantification\",\n      \"pmids\": [\"37964627\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ADRB2 signaling transcriptionally or post-transcriptionally regulates VMA21 not defined\", \"Not replicated in independent AD cohorts or models\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"VMA21 was shown to stabilize the V-ATPase a3 subunit TCIRG1 by direct binding and inhibition of its ubiquitination-mediated degradation, linking VMA21 to tumor proliferation and immune evasion in triple-negative breast cancer.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assay, VMA21 knockdown in TNBC cell lines, CD8⁺ T cell co-culture, xenograft model\",\n      \"pmids\": [\"39267677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether VMA21-TCIRG1 stabilization is independent of canonical V-ATPase assembly chaperone function not clarified\", \"No identification of the E3 ligase antagonized by VMA21\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of VMA21's interaction with V0 subunits, the distinct functional roles of VMA21-101 versus VMA21-120 in V-ATPase assembly, and the genotype–phenotype rules governing muscle versus liver disease remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of mammalian VMA21 or VMA21–V0 complex\", \"Isoform-specific V-ATPase assembly contributions not dissected\", \"Determinants of tissue-selective pathology (muscle vs liver vs lymphoma) undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [0, 1, 4, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [0, 1, 4, 7]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 1, 6]}\n    ],\n    \"complexes\": [\n      \"V-ATPase (V0 sector assembly intermediate)\"\n    ],\n    \"partners\": [\n      \"TCIRG1\",\n      \"ATP6V0A1\",\n      \"ATP6V0D1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}